1 2 0 9 B r i e f c o m m u n i c at i o n s ZIKV, a flavivirus transmitted primarily by Aedes mosquitoes, has spread to a growing number of countries. While most ZIKV-infected patients exhibit few or relatively mild symptoms, including mild fever, skin rash, conjunctivitis, muscle and joint pain, malaise or headache, prenatal ZIKV infection may cause microcephaly and other serious brain anomalies in fetuses or infants 1,2 . Recent studies of ZIKV pathogenesis in the CNS have shown that ZIKV crosses the placenta and causes microcephaly by targeting cortical neural progenitor cells, inducing cell death and impairing neurodevelopment [3] [4] [5] [6] [7] [8] . Other pronounced symptoms of ZIKV infection in children and adults are retro-orbital pain, abdominal pain and diarrhea 9 , which are associated with the PNS, and more specifically sensory and enteric neurons. In particular, peripheral neuropathy without any CNS symptom in a patient infected with ZIKV has been reported 10,11 , which is supported by persistent ZIKV detection in the PNS of rhesus macaques 12 . In addition, ZIKV causes Guillain-Barré syndrome (GBS) 1 , another PNS disorder. In contrast to CNS model systems [3] [4] [5] [6] , PNS model systems for investigating ZIKV pathology are limited.
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ZIKV, a flavivirus transmitted primarily by Aedes mosquitoes, has spread to a growing number of countries. While most ZIKV-infected patients exhibit few or relatively mild symptoms, including mild fever, skin rash, conjunctivitis, muscle and joint pain, malaise or headache, prenatal ZIKV infection may cause microcephaly and other serious brain anomalies in fetuses or infants 1, 2 . Recent studies of ZIKV pathogenesis in the CNS have shown that ZIKV crosses the placenta and causes microcephaly by targeting cortical neural progenitor cells, inducing cell death and impairing neurodevelopment [3] [4] [5] [6] [7] [8] . Other pronounced symptoms of ZIKV infection in children and adults are retro-orbital pain, abdominal pain and diarrhea 9 , which are associated with the PNS, and more specifically sensory and enteric neurons. In particular, peripheral neuropathy without any CNS symptom in a patient infected with ZIKV has been reported 10, 11 , which is supported by persistent ZIKV detection in the PNS of rhesus macaques 12 . In addition, ZIKV causes Guillain-Barré syndrome (GBS) 1 , another PNS disorder. In contrast to CNS model systems [3] [4] [5] [6] , PNS model systems for investigating ZIKV pathology are limited.
In this study, we investigated PNS infection of ZIKV using both in vivo and in vitro model systems.
We adopted type-I interferon receptor-deficient (A129) mice to generate a ZIKV infection model in vivo. ZIKV SZ01 was injected intraperitoneally into 5-week-old A129 mice, which were inspected 3 d later.
To determine the potential for ZIKV infection in the PNS, we examined the dorsal root ganglia (DRG) and small intestine from ZIKV-infected and mock-treated mice. We detected the presence of ZIKV in both DRG and small intestine with ZIKV antiserum (Supplementary Fig. 1a,b) . In addition, robust ZIKV signals colocalized with neuron-specific class III β-tubulin (Tuj1), indicating that mouse peripheral neurons in the DRG and gut were infected by ZIKV ( Supplementary Fig. 1a,b) . To test whether PNS infection of ZIKV could also occur in a mouse model of microcephaly 5 , we injected ZIKV SZ01 into the lateral ventricle of wild-type mouse brains at embryonic day (E) 13.5 and analyzed tissue at postnatal day (P) 1. We also detected ZIKV in the DRG, small intestine and spinal cord, with colocalization with neuronal markers Tuj1 and NeuN or cleaved caspase 3 (cl-Casp3; Fig. 1 and Supplementary Fig.  1c,d ), demonstrating that brain-injected ZIKV can infect and impact peripheral neurons in the mouse DRG and gut in vivo.
These in vivo observations prompted us to use a human stem-cell-based model to directly examine ZIKV infection and its molecular pathology. Neural crest cells are migratory multipotent progenitors that give rise to various cell types, including neurons and glia of the PNS 13 . We previously developed an efficient protocol 14 to differentiate human pluripotent stem cells (hPSCs) into human neural crest cells (hNCCs), which can be further differentiated into human peripheral neurons (hPNs) ( Supplementary  Fig. 2 ). We used a clinically isolated ZIKV strain from the 2015 Puerto Rico Zika outbreak, PRVABC59 (hereafter ZIKV PR ), which is closely related to epidemic strains circulating in the Americas that have been linked to in utero ZIKV infection 15 . We performed infections at a low or moderate multiplicity of infection (MOI; 0.04 or 0.4) for 2 h. Infection rates were quantified 65 h later with immunocytochemistry using an anti-ZIKV envelope protein (ZIKVE) antibody. hNCCs expressing neural crest markers were readily infected by ZIKV PR (Fig. 2a,b) . As in previous CNS model systems for ZIKV infection 3, 16 , the staining signal for ZIKVE was concentrated in the perinuclear structures of hNCCs (Fig.  2a) , and ZIKV PR infection reduced the cell viability of hNCCs compared to mock-infected cells ( Fig. 2c and Supplementary Fig. 3a) . These results are in accordance with a recent publication demonstrating that ZIKV infects cranial NCCs, resulting in reduced viability 17 Zika virus (ZIKV) infection is associated with neurological disorders of both the CNS and peripheral nervous systems (PNS), yet few studies have directly examined PNS infection. Here we show that intraperitoneally or intraventricularly injected ZIKV in the mouse can infect and impact peripheral neurons in vivo. Moreover, ZIKV productively infects stemcell-derived human neural crest cells and peripheral neurons in vitro, leading to increased cell death, transcriptional dysregulation and cell-type-specific molecular pathology. 
To investigate the impact of ZIKV PR infection on hNCCs at the molecular level, we employed global transcriptome analyses (RNA-seq). Our genome-wide analyses identified a large number of genes differentially expressed upon viral infection (Supplementary Fig. 4a,b and Supplementary Table 1) . Gene ontology (GO) analyses of ZIKV PR -infected hNCCs revealed a particular enrichment of upregulated genes in apoptotic, cell-death-related terms, which was more pronounced than in infected CNS human neural progenitor cells (hNPCs) 3, 16 , and enrichment in translation-related terms (Fig. 2d) . The downregulated genes were enriched in cell-cycle-related terms (Fig. 2e) , which is consistent with our previous findings in CNS hNPCs 3, 16 . Transcriptome-wide comparison of gene expression to ZIKV PR -infected CNS hNPCs revealed some similarities and differences ( Fig. 2f-i, Supplementary Fig. 5 and Supplementary Table 2) . Between ZIKV PR -infected hNCCs and CNS hNPCs, a number of genes were up-and downregulated in common (462 and 643 genes, respectively), but there were still many genes that were differentially expressed (874 genes in hNCCs and 5,116 genes in CNS hNPCs; Fig. 2f,g and Supplementary Fig. 5 ). Further GO analyses showed that genes in the term "translational elongation" were uniquely upregulated in ZIKV PR -infected hNCCs (false discovery rate (FDR) = 8.4 × 10 −39 ; Fig. 2h and Supplementary Fig. 5b ) and genes in the term "nucleosome organization" were uniquely downregulated in ZIKV PR -infected hNCCs compared to CNS hNPCs (FDR = 3.9 × 10 −8 ; Fig. 2i and Supplementary Fig. 5b ). This suggests that molecular pathology in ZIKV PR -infected hNCCs is distinct from that in CNS hNPCs.
Several recent studies have shown that in the CNS ZIKV targets NPCs, with little direct infection of neurons, both in culture and in vivo [3] [4] [5] [18] [19] [20] . In contrast, ZIKV PR readily infected hPNs expressing the neuronal markers peripherin (PRPH) and TUJ1 (Fig. 3a,b) . ZIKVE was concentrated in perinuclear structures of the hPSC-derived hPNs (Fig. 3a) , in accordance with a recent report that infectious ZIKV particles are located in the disrupted endoplasmic reticulum of CNS neurons in the human fetal brain 1 . ZIKV PR infection in hPNs led to reduced cell numbers compared to those in mock-infected cells ( Fig. 3c and Supplementary Fig. 3b ). Mechanistically, ZIKV PR infection increased CASP3 activation in hNCCs and hPNs 65 h after infection, as compared to mock infection, suggesting increased cell death ( Supplementary Fig. 3c-f) . Genome-wide transcription analyses of ZIKV PR -infected hPNs identified many differentially expressed genes upon viral infection ( Supplementary Fig. 4c,d and Supplementary Table 3 ). GO analyses of ZIKV PR -infected hPNs revealed that differential gene expression patterns were similar to that of ZIKV PRinfected hNCCs (Figs. 2d,e and 3d,e) , mainly associated with apoptotic cell death and cell cycle. In ZIKV PR -infected hPNs and hNCCs, large numbers of transcripts were differentially expressed (1,983 genes in hPNs and 945 genes in hNCCs), while a subset of these genes were up-and downregulated in common (419 and 615 genes, respectively; Supplementary  Figs. 6 and 7) . Further GO analyses with the list of differentially expressed genes unique to ZIKV PR -infected hPNs showed several enriched terms for downregulated genes, including "regulation of cell development" and "regulation of neurogenesis" (Supplementary Figs. 6g and 7a) , suggesting that ZIKV PR causes substantial developmental and cellular changes in hPNs. In particular, ZIKV PR disrupted "WNT signaling pathway" genes in infected hPNs (Supplementary Fig. 7b ), highlighting marked molecular perturbations upon ZIKV PR infection.
To verify our RNA-seq results, we focused on genes associated with apoptosis and epigenetic regulation, using quantitative real-time reverse transcription PCR (qRT-PCR), western blotting and immunocytochemical analyses (Supplementary Fig. 8 ). We confirmed that the expression and phosphorylation levels of c-Jun were increased only in ZIKV PR -infected hPNs (Supplementary Fig. 8c,e,f,i,j) , suggesting that c-Jun phosphorylation-associated apoptosis is one of the possible cell death pathways in ZIKV PR -infected hPNs (Supplementary Fig. 9 ). We also confirmed that the expression and acetylation levels of histone H3 were decreased only in ZIKV PR -infected hNCCs ( Supplementary  Fig. 8d,g,h) , indicating that dysregulation of histone protein expression and acetylation may be associated with cell death of ZIKV PRinfected hNCCs (Supplementary Fig. 9 ). Overall, our unbiased global transcriptome data sets not only support our findings of massive cell death in infected hNCCs and hPNs, but also provide a resource to the field for cell-type-specific molecular pathology caused by ZIKV PR .
While it has been established that ZIKV can cause neural developmental defects during brain development 6 , whether ZIKV can efficiently infect hPNs was not previously known. Here we demonstrated that either intraperitoneal injection or fetal mouse brain injection of ZIKV led to infection of the PNS. Both human stem-cell-derived hNCCs and hPNs were permissive to ZIKV infection, presenting far more cell death than Fig. 10 ), which suggests a tissue-specific vulnerability to ZIKV infection. Our results are also supported by recent human case studies and a primate model study that showed PNS ZIKV pathology [10] [11] [12] . We were also able to detect high levels of ZIKV in mouse spinal cord after intraventricular injection and secretion of infectious ZIKV particles from infected hNCCs and hPNs in culture ( Supplementary Fig. 11 RPS27  RPS29  RPLP1  RPS18  RPS15A  RPL13AP5  RPL39  RPS11  RPS8  RPL35  RPL9  RPS12  RPL31  RPS3A  RPL26  RPL30  RPL11  RPL27  RPS10  RPL19  RPL38  RPL35A  RPS19  RPL18A  RPL36  RPL12  RPS13  RPS25  RPS7  RPS15  RPS21  RPL13  EEF1B2  RPL37  RPL34  RPL15  RPL32  RPS20  RPL18  RPS5  FAU B r i e f c o m m u n i c at i o n s fluid and interneuronal transmission. It is also important to elucidate how PNS ZIKV infection is relevant to peripheral neuropathies. In summary, our study provides an efficient humanized model to study ZIKV infection in the PNS, showing similarities and differences in the molecular pathophysiology of ZIKV in the PNS compared to the developing CNS. Our study opens new avenues for further investigating cellular and molecular mechanisms, and our humanized peripheral neuron model can facilitate the discovery and validation of therapeutic agents for ZIKV-related PNS symptoms.
B r i e f c o m m u n i c at i o n s CNS cells. In addition, we found ZIKV infection in human stem-cellderived Schwann cells, but not in skeletal muscle cells (Supplementary
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Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. oNLINe MetHodS ZIKV preparation and animal infection. The Asian lineage ZIKV SZ01 strain (GenBank accession code KU866423) was isolated from a patient who had returned to China from Samoa and was amplified in C6/36 cells 21 . The ZIKV replicated efficiently in C6/36 cells and the viral growth curve was determined by qRT-PCR assay. Type-I interferon receptor-deficient (A129) mice were used to generate a ZIKV intraperitoneal infection model. Around 5 × 10 5 plaqueforming units (PFU) of ZIKV SZ01 or culture medium was injected intraperitoneally into 5-week-old A129 mice, which were inspected 3 d later. To generate the microcephaly mouse model, we anesthetized pregnant ICR mice at embryonic day 13.5 (E13.5), exposed the uterine horns and injected 1 µL of ZIKV SZ01 (6.5 × 10 5 PFU/mL) or culture medium (RPMI medium 1640 basic + 2% FBS) into the lateral ventricles of embryos using a calibrated micropipette, as described previously 5 . For each pregnant dam, two-thirds of the embryos received ZIKV infection while the rest were injected with culture medium to provide littermate controls. After virus injection, the embryos were placed back into the abdominal cavity of dams and wound was closed. Tissue was collected and analyzed at P1. All experimental procedures were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee at Beijing Institute of Microbiology and Epidemiology and conducted in a biological safety protection laboratory. The experimenters were blinded to treatment. None of the viable animals were excluded from our analyses.
Immunohistochemistry. The trunk tissues with dorsal root ganglion (DRG)
and spinal cord from the infected pups and their littermate controls were collected at P1. The tissues were fixed in 4% paraformaldehyde overnight, dehydrated with 20% sucrose in PBS and embedded in OCT compound for cryostat sectioning. The sections with DRG and spinal cord were immunostained with human convalescent serum from ZIKV-infected patients 5 and commercial primary antibodies (Supplementary Table 4) . For measuring the percentage of apoptotic DRG neurons labeled by cl-Casp3, we counted 10 tissue slices (30 µm/slice) from 4 pairs of animals under fluorescence microscopy. We did not dissect the DRG out of trunk tissues from P1 mice but directly sectioned the trunk tissue containing spinal cord and DRG. We obtained around 10 slices containing DRG tissues from among more than 30 slices for each group and counted the infected and apoptotic neurons for quantification. Some slices contain more than 150 DRG neurons but others had less than 50 DRG. We counted all slices with DRG neurons. Preparations of enteric ganglia were generated by peeling off the small intestinal villus layer from a freshly dissected segment of the jejunum. The stretched surface along with the attached myenteric plexus were fixed overnight in 4% PFA in PBS. The wholemounts were used for immunofluorescence staining. The experimenters were blinded to treatment. None of the viable animals were excluded from our analyses. We also did not exclude any data points from quantification.
hPSC culture and PNS differentiation. Undifferentiated H9 hESCs (passages 40-50) were cultured on mitotically inactivated mouse embryonic fibroblasts (MEFs, Applied Stem Cell) in hESC medium, consisting of DMEM/F12, 20% knockout serum replacement (KSR), 0.1 mM MEM-NEAA, 2 mM L-glutamine, 55 µM β-mercaptoethanol (Life Technologies) and 10 ng/mL FGF2 (R&D Systems). All cells were maintained at 37 °C and 5% CO 2 in a humidified incubator. For neural differentiation, hESCs were plated at 5-20 × 10 3 cells on a confluent layer of irradiated (50 Gy) stromal cells (MS-5) in 60-mm cell culture plates in a medium containing DMEM/F12, 20% KSR, 0.1 mM MEM-NEAA, 2 mM L-glutamine and 55 µM β-mercaptoethanol (KSR medium) as described previously 14, 22, 23 . After 16 d in KSR medium, cultures were switched to N2 medium 14, [22] [23] [24] . Medium was changed every 2 d, and growth factors were added as described previously 14, [22] [23] [24] . Briefly, differentiation was initiated by adding 100 nM LDN193189 (Abcam) and 10 µM SB431542 (Cayman Chemical) in KSR medium. Other small-molecule compounds used in neural induction and differentiation were as follows: 0.2 mM ascorbic acid, 0.2 mM dibutyryl cyclic AMP (Sigma-Aldrich) and 1 µM purmorphamine (PMP, Cayman Chemical). Recombinant growth factors were as follows: 50 ng/ml sonic hedgehog (Shh), 100 ng/ml FGF8 (R&D Systems) and 10 ng/ml BDNF (PeproTech). Rosette structures were harvested mechanically at day 22-28 of differentiation (termed passage 0; P0) and gently replated on 15 µg/ml polyornithine/1 µg/ml laminin/10 ng/ml fibronectin (PO/Lam/FN)-coated culture dishes in N2 medium (termed passage 1; P1). P1 cultures were supplemented with ascorbic acid, PMP, Shh, FGF8 and BDNF. . hPSC-derived hNCCs were maintained in hNCC medium, consisting of Neurobasal medium supplemented with 2 mM L-glutamine, B-27, N-2 supplements (Life Technologies), 20 ng/ml FGF2 and 20 ng/ml EGF (R&D Systems). For directed differentiation of hPSC-derived NCCs toward hPNs, FGF2/EGF-expanded hNCCs were differentiated for at least for 2 weeks with hPN medium, consisting of Neurobasal medium supplemented with 2 mM L-glutamine, B-27, N-2 supplements, 0.2 mM ascorbic acid, 0.2 mM dibutyryl cyclic AMP, 10 ng/mL BDNF, 10 ng/mL NGF (PeproTech) and 10 ng/mL GDNF (R&D Systems) 23 . For directed differentiation of hPSC-derived NCCs toward Schwann cells, we followed a previously described protocol 14, 22 . Myogenic differentiation and myotube formation followed a previously described protocol 25 .
hPSC culture and CNS hNPC differentiation. Human iPSC lines have been fully characterized 26 and were passaged on MEF feeder layers. All studies followed institutional IRB and ISCRO guidelines and protocols approved by Johns Hopkins University School of Medicine. Human iPSCs were differentiated into forebrainspecific hNPCs and immature neurons following a previously established protocol 26 . Briefly, hiPSCs colonies were detached from the feeder layer with 1 mg/mL collagenase treatment for 1 h and suspended in embryonic body (EB) medium, consisting of FGF2-free iPSC medium supplemented with 2 µM dorsomorphin and 2 µM A-83, in untreated polystyrene plates for 4 d with daily medium changes. After 4 d, EB medium was replaced by neural induction medium (hNPC medium), consisting of DMEM/F12, N2 supplement, NEAA, 2 µg/mL heparin and 2 µM cyclopamine. The floating EBs were then transferred to Matrigel-coated six-well plates at day 7 to form neural-tube-like rosettes. The attached rosettes were kept for 15 d with hNPC medium changed every other day. On day 22, the rosettes were picked mechanically and transferred to lowattachment plates (Corning) to form neurospheres in hNPC medium containing B27. The neurospheres were then dissociated with Accutase at 37 °C for 10 min and placed onto Matrigel-coated six-well plates at day 24 to form monolayer hNPCs in hNPC medium containing B27. These hNPCs expressed forebrain-specific progenitor markers, including NESTIN, PAX6, EMX-1, FOXG1 and OTX2 (ref. 26 ).
Preparation of ZIKV PR and cell infection.
The ZIKV PRVABC59 strain (ZIKV PR ) was obtained from ATCC (Manassas, VA) and subsequently amplified in Aedes albopictus clone C6/36 cells (ATCC). Briefly, C6/36 cells were inoculated with viral inoculum for 1 h at 28 °C in a low volume of medium (3 mL per T-75 flask), with rocking every 15 min, before the addition of an additional 17 mL medium. Virus-inoculated cells were then incubated at 28 °C for 6-7 d before harvesting the supernatant. C6/36-amplified ZIKV PR titer was determined by infecting Vero cells for 48 h with a methylcellulose overlay and analyzed for focus-forming units (FFU) per mL. In mock infections, an equal volume of spent uninfected C6/36 culture medium was used. hPSC-derived hNCCs were seeded at a density of 50 cells/mm 2 and maintained for 2-4 d before ZIKV infection. hNCC-derived hPNs were seeded at a density of 1,700 cells/mm 2 and matured for 2-3 weeks before ZIKV infection. Then these cells were infected with ZIKV PR at MOI of 0.04 or 0.4 and analyzed 65 h after infection after washing the cells three times with culture medium or PBS. The experimenter was not blinded to treatment. None of cell cultures were excluded from our analyses.
Immunocytochemistry. Cells were fixed in 4% paraformaldehyde and stained with primary antibodies (Supplementary Table 4 ) after permeabilization with 0.1% Triton X-100/0.5% BSA/PBS solution. Appropriate Alexa Fluor 488-or 568-labeled secondary antibody (Life Technologies) and DAPI (Roche Applied Science) nuclear counter-staining were used for visualization. The stained samples were analyzed using fluorescence microscopy (Eclipse TE2000-E, Nikon). The numbers of ZIKVE + , Ki-67 + or DAPI + cells per mm 2 were counted under fluorescence microscopy. Cell viability 65 h after ZIKV PR infection was represented as percentage fold change (relative to mock) of DAPI + cell number (per mm 2 ) in ZIKV PR -infected cells (mean ± s.e.m.). The experimenter was not blinded to treatment. None of cell cultures were excluded from our analyses.
RNA isolation, RNA-seq library preparation and sequencing. RNA-seq libraries were prepared from isolated total RNA and were sequenced as previously described 16 . Briefly, total cellular RNA was purified from cell pellets using TRIzol reagent (Life Technologies) according to the manufacturer's instructions. RNA-seq libraries were generated from 1 µg of total RNA from duplicated or triplicated samples (2 or 3 cell cultures) per condition using the TruSeq LT RNA Library Preparation Kit v2 (Illumina) following the manufacturer's protocol. An Agilent 2100 BioAnalyzer and DNA1000 kit (Agilent) were used to quantify amplified cDNA and to control the quality of the libraries. An Illumina HiSeq2500 or HiSeq3000 was used to perform 100-or 50-cycle single-read sequencing. Image processing and sequence extraction were performed using the standard cloud-based Illumina pipeline in BaseSpace. The experimenter was blinded to treatment.
Bioinformatic analyses. Single-end RNA-seq reads were first aligned to human transcriptome annotations and genome assembly (hg19) using TopHat 27 v2.0.13. Table 4 ). The bands were quantified by densitometry using ImageJ (NIH). The experimenter was not blinded to treatment. Uncropped blots are shown in Supplementary Figure 12 .
Viral titer by focus forming assay. Cells were infected with ZIKV PR at MOI of 0.04 for 65 h before harvesting the supernatant. Human cell amplified ZIKV PR titer was determined by infecting Vero cells for 48 h with a methylcellulose overlay and analyzed for FFUs per mL as previously described 31 . The experimenter was not blinded to treatment.
Statistical analysis. All data were tested for normal distribution. Values are from at least three independent experiments with multiple biological replicates each and reported as mean ± s.e.m. Differences between two samples were analyzed for significance using the unpaired two-tailed Student's t-test in Prism (GraphPad).
No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those reported in previous publications 3, 5, 16, 18, 22, 23, 26, 31 . Experimenters using in vivo samples were always blinded to treatment. No special randomization procedures were used for assigning groups.
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Data exclusions
Describe any data exclusions. None of the viable animals or cell cultures were excluded from our analyses. We also did not exclude any data points for quantification.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Whereas randomization was not feasible for in vitro study, batch effects were minimized through simultaneous processing of cases and controls for all experiments. For the ZIKV infection in the juvenile type-I interferon receptor deficient (A129) mice, we randomly grouped the animals and performed the ZIKV injection. To induce ZIKV-infection in the embryonic brains, we randomly selected two thirds of embryos for intraventricular ZIKV injection. After the birth of pups, we collected tissues from all of the viable mice without prior knowledge of whether the individual pups were ZIKV-infected or not. The identification completely relied on immunostaining with human ZIKV antibodies.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding was not utilized in vitro study. As primarily molecular techniques were utilized, investigator bias should play a minimal role in data acquisition in this particular study. For the embryonic infection model, we performed the experiment blindly. When we collected the DRG tissues from pups, we had no prior knowledge of which animals were infected with ZIKV. The samples were identified to be ZIKVpositive or negative by researchers in Dr. Zhiheng Xu's lab. The subsequent staining with cell markers and apoptotic marker were mainly performed in Dr. Qing-Feng Wu's lab.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
No unique materials were used.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). c. Report whether the cell lines were tested for mycoplasma contamination.
We have tested for mycoplasma contamination every other week and have continuously maintained a mycoplasma free laboratory for over five years.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
